Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||
Assets Current | ||||||||||||||||
Cash | 5 | 6 | 7 | 7 | 1 | 0 | 1 | 1 | 2 | 3 | 0 | |||||
Deferred Offering Costs | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Other Receivables | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | |||||
Other Receivables Net Current | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Assets Current | 5 | 6 | 7 | 7 | 1 | 0 | 1 | 1 | 2 | 4 | 0 | |||||
Deferred Costs | - | - | - | - | - | - | - | - | - | - | 4 | |||||
Assets | 5 | 6 | 7 | 7 | 1 | 0 | 1 | 1 | 2 | 4 | 5 | |||||
Liabilities And Stockhold… | ||||||||||||||||
Liabilities Current | ||||||||||||||||
Accounts Payable And Accrued Liabilities Current | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | |||||
Other Liabilities | - | - | - | - | - | - | - | 0 | 0 | 0 | 1 | |||||
Lines Of Credit Current | - | - | - | - | - | - | - | - | - | - | 0 | |||||
Loans Payable Current | 0 | 0 | - | - | - | - | - | - | - | - | - | |||||
Other Liabilities Current | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 1 | |||||
Liabilities Current | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | |||||
Liabilities | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | |||||
Stockholders Equity | ||||||||||||||||
Additional Paid In Capital | 49 | 47 | 47 | 46 | 38 | 33 | 31 | 28 | 23 | 23 | 18 | |||||
Retained Earnings Accumulated Deficit | -44 | -42 | -41 | -39 | -38 | -33 | -31 | -28 | -22 | -20 | -14 | |||||
Stockholders Equity | 5 | 5 | 6 | 7 | 0 | -0 | 1 | 0 | 2 | 3 | 3 | |||||
Liabilities And Stockholders Equity | 5 | 6 | 7 | 7 | 1 | 0 | 1 | 1 | 2 | 4 | 5 | |||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | |||||
Common Stock Shares Issued | 69 | 34 | 34 | 34 | 31 | 30 | 30 | 30 | 30 | 30 | 29 | |||||
Shares Outstanding | 69 | 34 | 34 | 34 | 31 | 30 | 30 | 30 | 30 | 30 | 29 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.72% | 0.00% | -1.57% | - | - | - | - | - | - | - | - | - |
| 2025 | -19.17% | -56.77% | -33.83% | -21.02% | -10.83% | -0.64% | 0.00% | -2.19% | -16.79% | -9.63% | -3.70% | -10.37% |
| 2024 | -15.47% | -34.98% | -49.85% | 14.70% | 20.94% | -5.35% | 55.61% | 7.88% | 15.99% | -11.21% | -12.32% | -43.40% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Telomir Pharmaceuticals, Inc. (TELO) — SEC Financial Statements & Analysis
Telomir Pharmaceuticals, Inc. (TELO) is a pharmaceutical preparations company, incorporated in FL. Telomir Pharmaceuticals, Inc. trades on Nasdaq as: TELO. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Telomir Pharmaceuticals, Inc. reported a Debt-to-Equity ratio of 0.07x, a Price-to-Book (P/B) ratio of 15.47x (TTM), at a market cap of $77.87M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.07x
- P/B TTM
- 15.47x
- Market Cap
- $77.87M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Telomir Pharmaceuticals, Inc. in?
Telomir Pharmaceuticals, Inc. (TELO) operates in the Pharmaceutical Preparations industry.
What is TELO's market cap?
Telomir Pharmaceuticals, Inc. (TELO) has a market capitalization of $77.87M as of 2026-06-30.
What exchange does TELO trade on?
Telomir Pharmaceuticals, Inc. (TELO) trades on the Nasdaq.
Where is Telomir Pharmaceuticals, Inc. incorporated?
Telomir Pharmaceuticals, Inc. is incorporated in FL.